A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2 Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (KATHERINE) Global Accrual = 1487
Patients with HER2-positive breast cancer with residual tumor in the breast and/or axillary lymph nodes following preoperative therapy.
Target Accrual: 366 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT01772472